NCT00467389

Use of Donepezil for Treatment of Cocaine Dependence

Donepezil Effects on Cocaine Craving and Pharmacokinetics

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: US Department of Veterans Affairs · Federal
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety of intravenous cocaine in subjects receiving oral donepezil.

Detailed description

This is a randomized, double-blind, double-dummy, placebo controlled, inpatient, single-center, parallel group evaluation of the potential for oral donepezil to attenuate cocaine-induced craving. Non-treatment-seeking cocaine-experienced volunteers will receive baseline treatment with intravenous cocaine (30Mg). Forty-two subjects that tolerate baseline cocaine infusions will then receive two subsequent intravenous doses of cocaine during double-blind treatment with oral placebo or 5 mg daily of donepezil. Each dose of cocaine will be preceded or followed by administration of intravenous placebo (saline) in a random order.

Conditions

• Cocaine Abuse and Dependence

Interventions

Type	Name	Description
DRUG	Donepezil, 5 mg daily	This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
OTHER	Oral Placebo	Inactive Comparator with Similar Appearance to Active Medication

Timeline

• Start date: 2007-02-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2007-04-30
• Last updated: 2014-06-09
• Results posted: 2014-06-09

Locations

1 site across 1 country: United States